|Bid||77.74 x 900|
|Ask||79.00 x 2900|
|Day's range||76.81 - 78.43|
|52-week range||53.22 - 78.43|
|Beta (5Y monthly)||0.54|
|PE ratio (TTM)||N/A|
|Earnings date||27 Apr 2022 - 02 May 2022|
|Forward dividend & yield||2.16 (2.85%)|
|Ex-dividend date||31 Mar 2022|
|1y target est||79.16|
Bristol Myers (BMY) phase III CheckMate -901 study fails to meet the primary endpoint of overall survival in patients with untreated unresectable or metastatic urothelial cancer.
PRINCETON, N.J., May 16, 2022--BMS Provides Update on CheckMate -901 Trial
BridgeBio (BBIO) forms an exclusive partnership with Bristol Myers (BMY) to develop and commercialize its SHP2 inhibitor.